Please login to the form below

Not currently logged in
Email:
Password:

Cancer Research UK

This page shows the latest Cancer Research UK news and features for those working in and with pharma, biotech and healthcare.

AZ’s comeback drug cediranib stumbles in phase 3 trial

AZ’s comeback drug cediranib stumbles in phase 3 trial

and cervical cancer indications, particularly the ICON6 study sponsored by Cancer Research UK. ... That results led to speculation that the combination could become a chemo-free option for relapsed ovarian cancer patients.

Latest news

More from news
Approximately 16 fully matching, plus 130 partially matching documents found.

Latest Intelligence

  • Building Europe’s next breakthrough biotechs Building Europe’s next breakthrough biotechs

    Its founding investors include Cambridge Innovation Capital, Babraham Research Campus through Babraham Bioscience Technologies, Roche's biotech arm Genentech, and Dr Jonathan Milner and Dr Ian Tomlinson, two of the ... life sciences campus in central

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    genetic research through to drug development in pharma, and into leadership of several successful UK biotech firms. ... She is also a Women of Influence Mentor for Cancer Research UK and a public governor for The Christie NHS Foundation Trust in

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    A recent review of the current landscape of clinical research in cancer immunotherapy counted more than 3, 000 trials enrolling patients, including more than 1, 000 trials evaluating combinations with ... This view is shared by Professor Charles Swanton,

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Scientists from the UK’s Medical Research Council Laboratory of Molecular Biology – which pioneered the sequencing of DNA – are already working with AstraZeneca counterparts and they will have places in the ... The park is also home to the Cancer

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098) originally developed for asthma in kidney cancer. ... Additional work is going to stratify tumours according to these molecular signatures, and

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio. ... Additionally, Dr Jon Roffey joins Glythera’s scientific advisory board (SAB) from Cancer

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    Workman currently serves The Institute of Cancer Researc h as its president and chief executive officer and has formerly served as head of the division of cancer therapeutics at Cancer Research ... world class cancer institute and being a founder of

  • Cancer Research UK's Karen Vousden to join BMS board Cancer Research UK's Karen Vousden to join BMS board

    Cancer Research UK's Karen Vousden is set to join Bristol-Myers Squibb’s board of directors in January. ... Vousden is currently chief scientist at Cancer Research UK, as well as serving as group leader at the Francis Crick Institute in London, will

  • Sophie Adlard joins J+D Consulting as a business analyst Sophie Adlard joins J+D Consulting as a business analyst

    She brings experience from Cancer Research UK, where she was a PhD student. ... market research and forecasting projects going forward.”.

  • Hollingsworth leaves cancer charity for ABPI Hollingsworth leaves cancer charity for ABPI

    Andrew Hollingsworth appointed policy manager at pharma industry body. Andrew Hollingsworth is to leave the third sector to join industry, moving from Cancer Research UK to the Association of the British ... He leaves his role as public affairs manager

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics